Cutting-Edge Aesthetic and Wellness Treatments, Delivered by the Same Expert Team with the Same Unmatched Quality

MedeAnalytics and Holon partner to launch Integrated Patient Insights to provide real-time patient insights for healthcare providers

New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market

Desert Stream Inc., a well-established nutritional and supplement manufacturer of caffeine-based products, engaged for sourcing of ingredients, lab studies, regulatory compliance, and quality control.

Single dose pre-workout supplement expected to be available in specialty retailers of nutritional products in 2025

The Competitive Edge in AI-Powered Senior Living 

Correction: The "About..." Section needed to be updated to reflect both Electronic Caregiver and Addison Care. As well as some grammar/spelling corrections. 

Public Data Shows PETA Caused Death for Thousands of Vulnerable Animals

Transforming Senior Living and Long-Term Care with AI-Driven Virtual Home Care at HIMSS 2025

mRESVIA^® is Moderna's second approved product in the UK

The Competitive Edge in AI-Powered Senior Living

Federal Probe Confirms Alpha Genesis' Highest Standards in Animal Welfare Compliance

TRNR details $50M pro forma annual revenue guidance, rationale of expected Sportstech acquisition, comments on market manipulation concerns and bitcoin as a Treasury asset

The updated website features more purchasing flexibility and an easier way for businesses to source wholesale essential oils and other fragrance supplies.

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease

A Revolutionary, Neurodivergent-Affirming Approach to Mental Health and Well-Being

Latest purchase confirms significant demand for CLMBR in Germany, quickly following on the initial order that was fulfilled in the Fall of 2024

Growing demand strengthens distributor relationship and validates TRNR's acquisition of German market leader Sportstech

Germany is the largest fitness market after the United States

Achieved Record Revenue for 2024 and Growth of 31%;

Reduced 2024 Operational Cash Burn by 35%

Case study shows Southeast Houston Cardiology's merger into region's leading physician-owned medical group increases case volume, slashes overhead expenses while boosting physician and patient satisfaction.

The patient edition of Chairside magazine educates patients on the power of dentistry

New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death

The Global Functional Mushroom Market is Set to Surpass $19 Billion by 2030—CBDL Enters the Booming Industry with Premium Mushroom Capsules for Cognitive Enhancement, Immune Support & Longevity!

Company Encourages Shareholders to Sign Up for Direct Email Updates

Rebranding heralds greater focus on building a future-ready global healthcare workforce 

This Press Release updates an error in the sub headline

Strategic Partnership: Royal Biologics and Coldplasmatech Revolutionize Complex Wound Care

Black Book Research Introduces 18 AI-Focused KPIs to Deeply Evaluate Machine Learning, Data Integration, and Real-World Impact in Population Health and Value-Based Care

New Industry KPIs for Evaluating PHM & VBC IT Vendors Prioritize AI-Driven Insights, Workflow Automation, and Real-World Clinical Impact - Top 2025 Vendors Recognized for Effectiveness and Client Experience

Strategic Partnership: RoStrategic Partnership: Royal Biologics and Coldplasmatech Revolutionize Complex Wound Careyal Biologics and Coldplasmatech Revolutionize Complex Wound Care

Innovative Redesign Brings Smaller, Cost-Effective Unit with Advanced Diagnostics to Consumers

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -

- The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis -

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete

Test results support the next development step with Phase 1clinical trial expected to commence in April

Provides Summary of Expected 2025 Milestones

DOHC won Best Home Health Care Services and Best Nurse/Nurse Practitioner

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Familial Chylomicronemia Syndrome

PharmPix further positions itself as a leader in the pharmacy benefit management arena as they are proud to announce their expansion into the Medicare market with the launch of MedArk™, a transformative platform designed to meet the complex needs of Medicare Part D plans.

During American Heart Month, the leading podiatry group is highlighting how evaluations of health issues with the feet can provide early detection of cardiovascular issues.

Spring Lake Ranch Therapeutic Community launches 18MM Capital Campaign.

What Does This Mean for the Future of EO Sterilization?

Meet Black Book top rated IT vendors at the AHA Rural Healthcare Leadership Conference

$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025

PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024

Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025

Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025

Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028